Jeffrey Melson Clarke | Scholars@Duke

Jeffrey Melson Clarke
Assistant Professor of Medicine

Current Appointments & Affiliations

Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2017
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2018

Contact Information

Dept of Medicine, Box 31379 Med Ctr, Durham, NC 27710
jeffrey.clarke@duke.edu (919) 684-8111

Background
Education, Training, & Certifications
- Hematology and Medical Oncology Fellowship, Medicine, Duke University School of Medicine 2011 - 2015
- Internal Medicine Chief Resident, Medicine, Duke University School of Medicine 2012 - 2013
- Categorical Internal Medicine Residency, Medicine, Duke University School of Medicine 2008 - 2011
- M.D., Indiana University, School of Medicine 2008
Previous Appointments & Affiliations
- Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2015 - 2017
- Medical Instructor in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2012 - 2013
Research
Selected Grants
External Relationships
- Adaptimmune Therapeutics Plc
- Amgen, Inc.
- AstraZeneca
- Cellular Biomedicine Group
- G1 Therapeutics, Inc.
- Genentech
- Grid Therapeutics, LLC
- Lung Cancer Initiative of North Carolina
- Merck & Co. USA (not assoc'd with Merck KGaA)
- Omega Therapeutics
- Pfizer Inc.
- Spectrum Pharmaceuticals Inc.
- TCR2 Therapeutics
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Villaruz, L. C., X. Wang, E. M. Bertino, L. Gu, S. J. Antonia, T. F. Burns, J. Clarke, et al. “A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.” Esmo Open 8, no. 2 (April 2023): 101183. https://doi.org/10.1016/j.esmoop.2023.101183.
    Full Text Link to Item
  - Bodd, Monica H., Susan C. Locke, Steve P. Wolf, Scott Antonia, Jeffrey Crawford, John Hartman, Kris W. Herring, et al. “Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.” Lung Cancer 175 (January 2023): 17–26. https://doi.org/10.1016/j.lungcan.2022.11.010.
    Full Text Link to Item
  - Hong, David S., Brian A. Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L. Johnson, Anthony J. Olszanski, Jeffrey M. Clarke, et al. “Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.” Nat Med 29, no. 1 (January 2023): 104–14. https://doi.org/10.1038/s41591-022-02128-z.
    Full Text Link to Item
  - Liveringhouse, Casey L., Kujtim Latifi, Amalin G. Asous, Nghi B. Lam, Stephen A. Rosenberg, Thomas J. Dilling, Gretchen V. MacMillan, et al. “Dose Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer.” International Journal of Radiation Oncology, Biology, Physics, January 2023, S0360-3016(23)00046-9. https://doi.org/10.1016/j.ijrobp.2023.01.006.
    Full Text
  - Clarke, Jeffrey M., Lin Gu, Xiaofei F. Wang, Thomas E. Stinchcombe, Marvaretta M. Stevenson, Sundhar Ramalingam, Afreen Shariff, et al. “A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial.” Jto Clin Res Rep 3, no. 6 (June 2022): 100337. https://doi.org/10.1016/j.jtocrr.2022.100337.
    Full Text Link to Item
  - Le, Xiuning, Robin Cornelissen, Marina Garassino, Jeffrey M. Clarke, Nishan Tchekmedyian, Jonathan W. Goldman, Szu-Yun Leu, et al. “Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.” J Clin Oncol 40, no. 7 (March 1, 2022): 710–18. https://doi.org/10.1200/JCO.21.01323.
    Full Text Link to Item
  - Gupta, Anjali, Dongyu Zhang, Dejana Braithwaite, Shama D. Karanth, Tina D. Tailor, Jeffrey M. Clarke, and Tomi Akinyemiju. “Racial Differences in Survival Among Advanced-stage Non-small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB).” Journal of Immunotherapy (Hagerstown, Md. : 1997) 45, no. 2 (February 2022): 132–37. https://doi.org/10.1097/cji.0000000000000400.
    Full Text
  - Rottey, Sylvie, Jeffrey Clarke, Kyaw Aung, Jean-Pascal Machiels, Ben Markman, Kimberley M. Heinhuis, Michael Millward, et al. “Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.” Clin Cancer Res 28, no. 1 (January 1, 2022): 95–105. https://doi.org/10.1158/1078-0432.CCR-21-1181.
    Full Text Link to Item
  - Clarke, Jeffrey M., Jyoti D. Patel, Francisco Robert, Ebenezer A. Kio, Eddie Thara, D. Ross Camidge, Martin Dunbar, Silpa Nuthalapati, Minh H. Dinh, and Bruce A. Bach. “Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.” Lung Cancer 161 (November 2021): 180–88. https://doi.org/10.1016/j.lungcan.2021.09.004.
    Full Text Link to Item
  - Kao, Chester, Eric Powers, Yuan Wu, Michael B. Datto, Michelle F. Green, John H. Strickler, Neal E. Ready, Tian Zhang, and Jeffrey M. Clarke. “Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.” Clin Lung Cancer 22, no. 6 (November 2021): 500–509. https://doi.org/10.1016/j.cllc.2021.03.017.
    Full Text Link to Item
  - Isaacs, James, Scott Antonia, and Jeffrey Clarke. “Immune Checkpoint Inhibitors in the Aged.” Curr Oncol Rep 23, no. 10 (August 3, 2021): 115. https://doi.org/10.1007/s11912-021-01106-x.
    Full Text Link to Item
  - Dorry, Michael, Kevin Davidson, Rajesh Dash, Rachel Jug, Jeffrey M. Clarke, Andrew B. Nixon, and Kamran Mahmood. “Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis.” Transl Lung Cancer Res 10, no. 6 (June 2021): 2500–2508. https://doi.org/10.21037/tlcr-21-123.
    Full Text Link to Item
  - Sidell, Douglas R., Karthik Balakrishnan, Simon R. Best, Karen Zur, Julia Buckingham, Alessandro De Alarcon, Fuad M. Baroody, et al. “Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.” Laryngoscope 131, no. 6 (June 2021): E1941–49. https://doi.org/10.1002/lary.29343.
    Full Text Link to Item
  - Deveaux, April E., Tyler A. Allen, Muthana Al Abo, Xiaodi Qin, Dadong Zhang, Brendon M. Patierno, Lin Gu, et al. “RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.” Lung Cancer 153 (March 2021): 90–98. https://doi.org/10.1016/j.lungcan.2021.01.015.
    Full Text Link to Item
  - Lee, Tristan, Jeffrey M. Clarke, Deepali Jain, Sendhilnathan Ramalingam, and Vishal Vashistha. “Precision treatment for metastatic non-small cell lung cancer: A conceptual overview.” Cleve Clin J Med 88, no. 2 (February 1, 2021): 117–27. https://doi.org/10.3949/ccjm.88a.19148.
    Full Text Link to Item
  - Chodavadia, Parth A., Corbin D. Jacobs, Frances Wang, Joseph K. Salama, Chris R. Kelsey, Jeffrey M. Clarke, Neal E. Ready, and Jordan A. Torok. “Synergy between early-incorporation immunotherapy and extracranial radiotherapy in metastatic non-small cell lung cancer.” Transl Lung Cancer Res 10, no. 1 (January 2021): 261–73. https://doi.org/10.21037/tlcr-20-537.
    Full Text Link to Item
  - Shen, Erica, Amanda E. D. Van Swearingen, Meghan J. Price, Ketan Bulsara, Roeland G. W. Verhaak, César Baëta, Brice D. Painter, et al. “A Need for More Molecular Profiling in Brain Metastases.” Front Oncol 11 (2021): 785064. https://doi.org/10.3389/fonc.2021.785064.
    Full Text Link to Item
  - Negrao, Marcelo V., Victoria M. Raymond, Richard B. Lanman, Jacqulyne P. Robichaux, Junqin He, Monique B. Nilsson, Patrick K. S. Ng, et al. “Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.” J Thorac Oncol 15, no. 10 (October 2020): 1611–23. https://doi.org/10.1016/j.jtho.2020.05.021.
    Full Text Link to Item
  - Tang, Dongfang, Yu C. Zhao, Hongliang Liu, Sheng Luo, Jeffrey M. Clarke, Carolyn Glass, Li Su, et al. “Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer.” Int J Cancer 147, no. 6 (September 15, 2020): 1559–70. https://doi.org/10.1002/ijc.32932.
    Full Text Open Access Copy Link to Item
  - Jung, Su Young, Sunjin Hwang, Jeffery M. Clarke, Todd M. Bauer, Vicki L. Keedy, Hukeun Lee, Neunggyu Park, Seong-Jin Kim, and Jangik I. Lee. “Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.” Invest New Drugs 38, no. 3 (June 2020): 812–20. https://doi.org/10.1007/s10637-019-00835-y.
    Full Text Link to Item
  - Deng, Wei, Hongliang Liu, Sheng Luo, Jeffrey Clarke, Carolyn Glass, Li Su, Lijuan Lin, David C. Christiani, and Qingyi Wei. “APOB Genotypes and CDH13 Haplotypes in the Cholesterol-Related Pathway Genes Predict Non-Small Cell Lung Cancer Survival.” Cancer Epidemiol Biomarkers Prev 29, no. 6 (June 2020): 1204–13. https://doi.org/10.1158/1055-9965.EPI-19-1262.
    Full Text Open Access Copy Link to Item
  - Jacobs, Corbin D., Junheng Gao, Xiaofei Wang, Jeffrey M. Clarke, Betty Tong, Neal E. Ready, Gita Suneja, Chris R. Kelsey, and Jordan A. Torok. “Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness.” Clin Lung Cancer 21, no. 3 (May 2020): 238–46. https://doi.org/10.1016/j.cllc.2019.10.005.
    Full Text Link to Item
  - Moravan, Michael J., Peter E. Fecci, Carey K. Anders, Jeffrey M. Clarke, April K. S. Salama, Justus D. Adamson, Scott R. Floyd, et al. “Current multidisciplinary management of brain metastases.” Cancer 126, no. 7 (April 1, 2020): 1390–1406. https://doi.org/10.1002/cncr.32714.
    Full Text Link to Item
  - Jug, Rachel, Coral X. Giovacchini, Beiyu Liu, Cynthia L. Green, Jeffrey M. Clarke, Kamran Mahmood, and Elizabeth N. Pavlisko. “EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.” J Am Soc Cytopathol 9, no. 6 (2020): 485–93. https://doi.org/10.1016/j.jasc.2020.04.003.
    Full Text Link to Item
  - Jung, Su Young, Ji Seob Yug, Jeffery M. Clarke, Todd M. Bauer, Vicki L. Keedy, Sunjin Hwang, Seong-Jin Kim, Eun Kyoung Chung, and Jangik I. Lee. “Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors.” Cancer Chemother Pharmacol 85, no. 1 (January 2020): 173–83. https://doi.org/10.1007/s00280-019-03979-z.
    Full Text Link to Item
  - Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.
    Full Text Link to Item
  - Marano, A. L., J. M. Clarke, M. A. Morse, A. Shah, W. Barrow, M. A. Selim, R. P. Hall, and A. R. Cardones. “Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.” Br J Dermatol 181, no. 3 (September 2019): 580–83. https://doi.org/10.1111/bjd.17245.
    Full Text Link to Item
  - Tan, Irena, Thomas E. Stinchcombe, Neal E. Ready, Jeffrey Crawford, Michael B. Datto, Rebecca J. Nagy, Richard B. Lanman, Lin Gu, and Jeffrey M. Clarke. “Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study.” Transl Lung Cancer Res 8, no. 3 (June 2019): 258–67. https://doi.org/10.21037/tlcr.2019.04.03.
    Full Text Link to Item
  - DeMaio, Andrew, Jeffrey M. Clarke, Rajesh Dash, Siby Sebastian, Momen M. Wahidi, Scott L. Shofer, George Z. Cheng, Xuechan Li, Xiaofei Wang, and Kamran Mahmood. “Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.” J Bronchology Interv Pulmonol 26, no. 2 (April 2019): 96–101. https://doi.org/10.1097/LBR.0000000000000534.
    Full Text Link to Item
  - Pabla, Sarabjot, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, et al. “Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.” J Immunother Cancer 7, no. 1 (February 1, 2019): 27. https://doi.org/10.1186/s40425-019-0506-3.
    Full Text Link to Item
  - Shariff, Afreen Idris, Sohail Syed, Rebecca A. Shelby, Jeremy Force, Jeffrey Melson Clarke, David D’Alessio, and Leonor Corsino. “Novel cancer therapies and their association with diabetes.” J Mol Endocrinol 62, no. 2 (February 1, 2019): R187–99. https://doi.org/10.1530/JME-18-0002.
    Full Text Link to Item
  - Conroy, Jeffrey M., Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, et al. “Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.” J Immunother Cancer 7, no. 1 (January 24, 2019): 18. https://doi.org/10.1186/s40425-018-0489-5.
    Full Text Link to Item
  - Velikova, Galina, Linda Jane Williams, Sarah Willis, J Michael Dixon, Juliette Loncaster, Matthew Hatton, Jacqueline Clarke, Ian H. Kunkler, Nicola S. Russell, and Nicola S. MRC SUPREMO trial UK investigators. “Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.” Lancet Oncol 19, no. 11 (November 2018): 1516–29. https://doi.org/10.1016/S1470-2045(18)30515-1.
    Full Text Link to Item
  - Clarke, Jeffrey M., Daniel J. George, Stacey Lisi, and April K. S. Salama. “Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.” Target Oncol 13, no. 1 (February 2018): 1–20. https://doi.org/10.1007/s11523-017-0549-7.
    Full Text Link to Item
  - Jacobs, M. T., N. A. Mohindra, L. Shantzer, I. L. Chen, H. Phull, W. Mitchell, V. M. Raymond, et al. “Use of low-frequency driver mutations detected by cell-free circulating tumor DNA to guide targeted therapy in non-small-cell lung cancer: A multicenter case series.” Jco Precision Oncology 2 (January 1, 2018): 1–10. https://doi.org/10.1200/PO.17.00318.
    Full Text
  - Yi, John S., Neal Ready, Patrick Healy, Chelsae Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, et al. “Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.” Clin Cancer Res 23, no. 24 (December 15, 2017): 7474–82. https://doi.org/10.1158/1078-0432.CCR-17-2005.
    Full Text Link to Item
  - Nayar, Gautam, Tiffany Ejikeme, Pakawat Chongsathidkiet, Aladine A. Elsamadicy, Kimberly L. Blackwell, Jeffrey M. Clarke, Shivanand P. Lad, and Peter E. Fecci. “Leptomeningeal disease: current diagnostic and therapeutic strategies.” Oncotarget 8, no. 42 (September 22, 2017): 73312–28. https://doi.org/10.18632/oncotarget.20272.
    Full Text Link to Item
  - Bedoya, Armando, Kristen Glisinski, Jeffrey Clarke, Richard N. Lind, Charles Edward Buckley, and Scott Shofer. “Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.” Am J Case Rep 18 (July 31, 2017): 842–46. https://doi.org/10.12659/ajcr.904416.
    Full Text Open Access Copy Link to Item
  - Clarke, Jeffrey M., Xiaofei Wang, and Neal E. Ready. “Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?” Transl Lung Cancer Res 4, no. 6 (December 2015): 804–8. https://doi.org/10.3978/j.issn.2218-6751.2015.05.03.
    Full Text Link to Item
  - Lyman, Gary H., Kari Bohlke, Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan Ignacio Arcelus, Edward P. Balaban, et al. “Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.” J Clin Oncol 33, no. 6 (February 20, 2015): 654–56. https://doi.org/10.1200/JCO.2014.59.7351.
    Full Text Link to Item
  - Hatch, Ace J., Jeffrey M. Clarke, Andrew B. Nixon, and Herbert I. Hurwitz. “Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.” Cancer J 21, no. 4 (2015): 322–26. https://doi.org/10.1097/PPO.0000000000000129.
    Full Text Link to Item
  - Clarke, J. M., H. I. Hurwitz, and F. Rangwala. “Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.” Cancer Treat Rev 40, no. 9 (October 2014): 1065–72. https://doi.org/10.1016/j.ctrv.2014.07.001.
    Full Text Link to Item
  - Clarke, Jeffrey M., and Herbert I. Hurwitz. “Understanding and targeting resistance to anti-angiogenic therapies.” J Gastrointest Oncol 4, no. 3 (September 2013): 253–63. https://doi.org/10.3978/j.issn.2078-6891.2013.036.
    Full Text Link to Item
  - Clarke, Jeffrey Melson, and Herbert I. Hurwitz. “Targeted inhibition of VEGF receptor 2: an update on ramucirumab.” Expert Opin Biol Ther 13, no. 8 (August 2013): 1187–96. https://doi.org/10.1517/14712598.2013.810717.
    Full Text Link to Item
  - Lyman, Gary H., Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan Ignacio Arcelus, Edward P. Balaban, Jeffrey M. Clarke, et al. “Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.” J Clin Oncol 31, no. 17 (June 10, 2013): 2189–2204. https://doi.org/10.1200/JCO.2013.49.1118.
    Full Text Link to Item
  - Clarke, J. M., and A. J. Armstrong. “Novel therapies for the treatment of advanced prostate cancer.” Curr Treat Options Oncol 14, no. 1 (March 2013): 109–26. https://doi.org/10.1007/s11864-012-0222-4.
    Full Text Link to Item
  - Mis, L., and J. M. Clarke. “Ipilimumab-induced pneumonitis: A case report.” Journal of Pharmacy Technology 29, no. 2 (January 1, 2013): 94–98. https://doi.org/10.1177/875512251302900207.
    Full Text
  - Clarke, Jeffrey M., and Herbert I. Hurwitz. “Ziv-aflibercept: binding to more than VEGF-A--does more matter?” Nat Rev Clin Oncol 10, no. 1 (January 2013): 10–11. https://doi.org/10.1038/nrclinonc.2012.197.
    Full Text Link to Item
  - Clarke, Jeffrey M., and Paul Helft. “Long-term survival of a woman with well differentiated papillary mesothelioma of the peritoneum: a case report and review of the literature.” J Med Case Rep 4 (October 29, 2010): 346. https://doi.org/10.1186/1752-1947-4-346.
    Full Text Link to Item
  - Clarke, Jeffrey M., Michael A. Morse, H Kim Lyerly, Timothy Clay, and Tayuka Osada. “Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.” Expert Opin Biol Ther 10, no. 6 (June 2010): 875–83. https://doi.org/10.1517/14712591003798278.
    Full Text Link to Item
  - Struck, A., T. Howard, E. G. Chiorean, J. M. Clarke, R. Riffenburgh, and H. R. Cardenes. “Non-ampullary duodenal adenocarcinoma: Factors important for relapse and survival (Journal of Surgical Oncology (2009) 100, 2, (144-148)).” Journal of Surgical Oncology 100, no. 5 (October 1, 2009): 434. https://doi.org/10.1002/jso.21396.
    Full Text
  - Struck, Aaron, Thomas Howard, Elena G. Chiorean, Jeffrey M. Clarke, Robert Riffenburgh, and Higinia R. Cardenes. “Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival.” J Surg Oncol 100, no. 2 (August 1, 2009): 144–48. https://doi.org/10.1002/jso.21319.
    Full Text Link to Item
- Book Sections
  - Isaacs, J., and J. Clarke. “Lung cancer.” In Genomic and Precision Medicine: Oncology, Third Edition, 123–61, 2022. https://doi.org/10.1016/B978-0-12-800684-9.00006-X.
    Full Text
  - DeVito, N., M. A. Morse, B. Hanks, and J. M. Clarke. “Immune Checkpoint Combinations with Inflammatory Pathway Modulators.” In Current Cancer Research, 219–41, 2018. https://doi.org/10.1007/978-3-319-63757-0_8.
    Full Text
- Conference Papers
  - Lee, J. I., S. Y. Jung, J. S. Yug, E. K. Chung, V. L. Keedy, T. M. Bauer, J. M. Clarke, et al. “POPULATION PHARMACOKINETICS OF A NOVEL TGF-BETA RECEPTOR I KINASE INHIBITOR VACTOSERTIB IN PATIENTS WITH ADVANCED-STAGE SOLID TUMORS.” In Clinical Pharmacology & Therapeutics, 105:S103–S103. WILEY, 2019.
    Link to Item
  - Tan, Irena, Tom Stinchcombe, Neal E. Ready, Michael B. Datto, Rebecca J. Nagy, Lin Gu, and Jeffrey Melson Clarke. “Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: A single institution, retrospective cohort study.” In Journal of Clinical Oncology, 36:e21222–e21222. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e21222.
    Full Text
  - Patel, Sandip Pravin, Scott Morris, Young Kwang Chae, and Jeffrey Melson Clarke. “RNA turbulence by tumor type: Overexpression of actionable mRNA signaling pathways by histology.” In Journal of Clinical Oncology, 35:e23213–e23213. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e23213.
    Full Text
  - Yi, John, Jeffrey Melson Clarke, Patrick Healy, Xiaofei F. Wang, Debra Shoemaker, Mark W. Onaitis, Chelsae Dumbauld, et al. “Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, 35:26–26. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.7_suppl.26.
    Full Text
  - Demaio, A., R. C. Dash, S. Sebastian, J. M. Clarke, M. M. Wahidi, and K. Mahmood. “Comprehensive Genetic Mutation Analysis On Pleural Effusions Related To Lung Adenocarcinoma.” In American Journal of Respiratory and Critical Care Medicine, Vol. 195. AMER THORACIC SOC, 2017.
    Link to Item
  - Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).” In Journal of Clinical Oncology, 34:e15013–e15013. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e15013.
    Full Text
  - Clarke, Jeffrey Melson, Herbert Pang, Mark D. Starr, Ace Joseph Hatch, Hedy Lee Kindler, Eileen Mary O’Reilly, Federico Innocenti, Alan P. Venook, Herbert Hurwitz, and Andrew B. Nixon. “Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).” In Journal of Clinical Oncology, 33:306–306. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.306.
    Full Text
  - Liu, Yingmiao, Jeffrey Melson Clarke, Mark D. Starr, John C. Brady, Herbert Pang, Christel Rushing, Delia Alvarez, et al. “Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.” In Journal of Clinical Oncology, 32:11020–11020. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.11020.
    Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Conference Papers